Methylmalonicaciduria, vitamin B12 unresponsive, mut-0

Methylmalonicaciduria, vitamin B12 unresponsive, mut-0 is a rare genetic disorder characterized by the body's inability to properly process certain fats and proteins. This condition is a form of methylmalonic acidemia (MMA), specifically the mut-0 subtype, which is considered the most severe form due to its complete lack of methylmalonyl-CoA mutase enzyme activity. This enzyme is crucial for the metabolism of certain amino acids, lipids, and cholesterol. The mut-0 subtype does not respond to treatment with vitamin B12, distinguishing it from other forms of MMA that might show some level of improvement with vitamin B12 supplementation.

Symptoms and Diagnosis

Individuals with methylmalonicaciduria, vitamin B12 unresponsive, mut-0, typically present with symptoms early in life, often within the first week after birth. Symptoms can include vomiting, lethargy, failure to thrive, developmental delay, and more severe neurological complications such as seizures. Due to the nonspecific nature of these symptoms, diagnosis often requires specific biochemical tests that measure methylmalonic acid levels in the blood and urine. Genetic testing can confirm the diagnosis by identifying mutations in the MUT gene, which is responsible for encoding the methylmalonyl-CoA mutase enzyme.

Treatment and Management

As the mut-0 subtype is unresponsive to vitamin B12, treatment focuses on dietary management to restrict the intake of certain amino acids that the body cannot properly metabolize. This includes a low-protein diet supplemented with special medical formulas that do not contain the amino acids that contribute to toxic levels of methylmalonic acid in the body. Additionally, patients may require regular hemodialysis or peritoneal dialysis to remove excess methylmalonic acid from the blood. Liver or combined liver and kidney transplantation has been explored as a treatment option for severe cases, though this approach carries significant risks and challenges.

Prognosis

The prognosis for individuals with methylmalonicaciduria, vitamin B12 unresponsive, mut-0 varies. Early diagnosis and management can improve outcomes, but the disease often progresses to cause significant neurological damage and other complications. The severity of symptoms and the risk of life-threatening metabolic crises necessitate ongoing medical care and monitoring.

Epidemiology

Methylmalonicaciduria, vitamin B12 unresponsive, mut-0, is an extremely rare disorder. The exact prevalence is difficult to determine, but it is estimated to occur in less than 1 in 50,000 to 100,000 live births worldwide. It is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected by the disorder.

Methylmalonicaciduria, vitamin B12 unresponsive, mut-0 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia